241 related articles for article (PubMed ID: 29048560)
1. Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.
Olmez I; Love S; Xiao A; Manigat L; Randolph P; McKenna BD; Neal BP; Boroda S; Li M; Brenneman B; Abounader R; Floyd D; Lee J; Nakano I; Godlewski J; Bronisz A; Sulman EP; Mayo M; Gioeli D; Weber M; Harris TE; Purow B
Neuro Oncol; 2018 Jan; 20(2):192-202. PubMed ID: 29048560
[TBL] [Abstract][Full Text] [Related]
2. Identification of ritanserin analogs that display DGK isoform specificity.
Granade ME; Manigat LC; Lemke MC; Purow BW; Harris TE
Biochem Pharmacol; 2022 Mar; 197():114908. PubMed ID: 34999054
[TBL] [Abstract][Full Text] [Related]
3. Dual activities of ritanserin and R59022 as DGKα inhibitors and serotonin receptor antagonists.
Boroda S; Niccum M; Raje V; Purow BW; Harris TE
Biochem Pharmacol; 2017 Jan; 123():29-39. PubMed ID: 27974147
[TBL] [Abstract][Full Text] [Related]
4. Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.
Dominguez CL; Floyd DH; Xiao A; Mullins GR; Kefas BA; Xin W; Yacur MN; Abounader R; Lee JK; Wilson GM; Harris TE; Purow BW
Cancer Discov; 2013 Jul; 3(7):782-97. PubMed ID: 23558954
[TBL] [Abstract][Full Text] [Related]
5. miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
Yang F; Liu X; Liu Y; Liu Y; Zhang C; Wang Z; Jiang T; Wang Y
Cancer Lett; 2017 Jun; 396():1-9. PubMed ID: 28286260
[TBL] [Abstract][Full Text] [Related]
6. Delivering Glioblastoma a Kick-DGKα Inhibition as a Promising Therapeutic Strategy for GBM.
Purow B
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267577
[TBL] [Abstract][Full Text] [Related]
7. Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals.
Arranz-Nicolás J; Ogando J; Soutar D; Arcos-Pérez R; Meraviglia-Crivelli D; Mañes S; Mérida I; Ávila-Flores A
Cancer Immunol Immunother; 2018 Jun; 67(6):965-980. PubMed ID: 29572701
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
Velnati S; Ruffo E; Massarotti A; Talmon M; Varma KSS; Gesu A; Fresu LG; Snow AL; Bertoni A; Capello D; Tron GC; Graziani A; Baldanzi G
Eur J Med Chem; 2019 Feb; 164():378-390. PubMed ID: 30611057
[TBL] [Abstract][Full Text] [Related]
9. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
10. Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-κB pathway.
Wang H; Li L; Yin L
Biochem Biophys Res Commun; 2018 Jun; 500(2):518-524. PubMed ID: 29678575
[TBL] [Abstract][Full Text] [Related]
11. Prosaposin is a biomarker of mesenchymal glioblastoma and regulates mesenchymal transition through the TGF-β1/Smad signaling pathway.
Jiang Y; Zhou J; Hou D; Luo P; Gao H; Ma Y; Chen YS; Li L; Zou D; Zhang H; Zhang Y; Jing Z
J Pathol; 2019 Sep; 249(1):26-38. PubMed ID: 30953361
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer.
Purow B
Clin Cancer Res; 2015 Nov; 21(22):5008-12. PubMed ID: 26420856
[TBL] [Abstract][Full Text] [Related]
13. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA
Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Koch K; Hartmann R; Schröter F; Suwala AK; Maciaczyk D; Krüger AC; Willbold D; Kahlert UD; Maciaczyk J
Oncotarget; 2016 Nov; 7(45):73414-73431. PubMed ID: 27705917
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibition is more active against the glioblastoma proneural subtype.
Li M; Xiao A; Floyd D; Olmez I; Lee J; Godlewski J; Bronisz A; Bhat KPL; Sulman EP; Nakano I; Purow B
Oncotarget; 2017 Aug; 8(33):55319-55331. PubMed ID: 28903422
[TBL] [Abstract][Full Text] [Related]
18. GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma.
Moreno M; Pedrosa L; Paré L; Pineda E; Bejarano L; Martínez J; Balasubramaniyan V; Ezhilarasan R; Kallarackal N; Kim SH; Wang J; Audia A; Conroy S; Marin M; Ribalta T; Pujol T; Herreros A; Tortosa A; Mira H; Alonso MM; Gómez-Manzano C; Graus F; Sulman EP; Piao X; Nakano I; Prat A; Bhat KP; de la Iglesia N
Cell Rep; 2017 Nov; 21(8):2183-2197. PubMed ID: 29166609
[TBL] [Abstract][Full Text] [Related]
19. Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma.
Fedele M; Cerchia L; Pegoraro S; Sgarra R; Manfioletti G
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31167470
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
